As reported by the San Francisco Business Times , Art will leave May 1, followed by Sue Desmond-Hellmann and other senior execs later this year. No specific dates were noted for Sue Desmond-Hellman and the others leaving the company. [Update 5/1/2009 : Yesterday was Sue’s last day at Genentech. The SF Business Times reported that she has been recommended by a search committee to be the new chancellor of the University of California San Francisco. )
In a nice nod, Art will serve as an advisor to Genentech’s research and early development center and will join the Scientific Resource Board, Genentech’s external advisory group.
Art will be nominated as a member of the board of Roche Holding Ltd. at the 2010 shareholder general meeting.
As I noted a couple of weeks ago (here ), folks like Art are unlikely to kick around after someone’s acquired their company. As someone who is respected and liked, and has a track record that is the envy of many, Levinson will have a great number of options. Though it’s possible he will retire (and actually do nothing), it’s unlikely given his past track record. And it’s also worth noting that he rubs shoulders through board service with people like Google’s Eric Schmidt and Apple’s Steve Jobs, all people who show no signing up heading to the beach anytime soon.